IMRICOR MEDICAL SYSTEMS INC (IMR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMR

IMR - IMRICOR MEDICAL SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: N/A
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.39

06 Nov
2025

-0.060

OPEN

$1.49

-4.14%

HIGH

$1.49

155,726

LOW

$1.39

TARGET
$2.22 59.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IMR: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 8.7 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-20.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1.5 M
Book Value Per Share xxxxxxxxxxxxxxx-4.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-23.6 M
Net Profit Margin xxxxxxxxxxxxxxx-3,094.86 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-393.74 %
Return on Assets xxxxxxxxxxxxxxx-191.15 %
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-195.92 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-23.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx34 M
Total Debt xxxxxxxxxxxxxxx34 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx8.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx3 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx23 M
Research & Development xxxxxxxxxxxxxxx12 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

06/11/2025

1

Speculative Buy

$2.22

59.71%

Morgans sees Imricor Medical Systems' completion of the world’s first ischemic VT ablation fully under real-time MRI guidance, in collaboration with Amsterdam University, as a major milestone.

The procedure achieved several global firsts, including MRI-guided transseptal crossing, mapping, and ablation with Vision-MR catheters. The patient was non-inducible for VT post-procedure, confirming acute success.

The broker expects this success to drive adoption and trial expansion in Europe.

The company ended 3Q25 with US$45.7m cash and a US$4.8m operating outflow. No changes to forecasts.

Speculative Buy. Target unchanged at $2.22.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -8.72 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -5.45 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Taylor Collison

30/10/2025

2

Outperform

$2.26

62.59%

Taylor Collison's industry checks at the Atrial Fibrillation Symposium in Adelaide reaffirmed strong clinical and commercial validation for Imricor Medical Systems' real-time MRI-guided (iCMR) ablation platform.

Key opinion leaders highlighted the technology’s potential to expand from redo and VT ablations into first-line AF procedures, potentially doubling the addressable market to US$2bn.

The integration of Pulse Field Ablation (PFA) capabilities, supported by successful preclinical trials, underscores platform flexibility and positions Imricor Medical Systems ahead of the next ablation technology wave.

Clinician feedback continues to emphasise improved soft-tissue visualisation, lesion durability, and procedural safety as key differentiators driving adoption.

Outperform rating maintained with a $2.26 target price, rising to $3.76 under a higher AF market penetration scenario.

FORECAST
Taylor Collison forecasts a full year FY26 dividend of 0.00 cents and EPS of 16.35 cents.
Taylor Collison forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.77 cents.
Access Extra Coverage Research History >

IMR STOCK CHART

FNArena News on IMR

1
Australian Broker Call *Extra* Edition – Nov 06, 2025

Nov 06 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 30, 2025

Oct 30 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Oct 28, 2025

Oct 28 2025 - Daily Market Reports
4
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Sep 02, 2025

Sep 02 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
2
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
3
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
4
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
5
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
6
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
7
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
8
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
9
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
10
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus